367 related articles for article (PubMed ID: 21474903)
1. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
2. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
3. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
4. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Bobo WV
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
[TBL] [Abstract][Full Text] [Related]
5. Update on newer antipsychotic drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Apr; 49(4):13-5. PubMed ID: 21446639
[TBL] [Abstract][Full Text] [Related]
6. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.
Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Clin Neuropharmacol; 2013; 36(6):223-38. PubMed ID: 24201235
[TBL] [Abstract][Full Text] [Related]
7. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
8. Newer antipsychotics and upcoming molecules for schizophrenia.
George M; Amrutheshwar R; Rajkumar RP; Kattimani S; Dkhar SA
Eur J Clin Pharmacol; 2013 Aug; 69(8):1497-509. PubMed ID: 23545936
[TBL] [Abstract][Full Text] [Related]
9. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
[TBL] [Abstract][Full Text] [Related]
11. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Citrome L
Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
[TBL] [Abstract][Full Text] [Related]
12. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
13. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
Citrome L
CNS Drugs; 2013 Nov; 27(11):879-911. PubMed ID: 24062193
[TBL] [Abstract][Full Text] [Related]
14. Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
Stassinos G; Klein-Schwartz W
Clin Toxicol (Phila); 2018 May; 56(5):355-359. PubMed ID: 28992737
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
17. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Ben Gharbia M; Garnier M; Llorca PM
Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
[TBL] [Abstract][Full Text] [Related]
18. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
[TBL] [Abstract][Full Text] [Related]
19. Lurasidone : in the treatment of schizophrenia.
Sanford M
CNS Drugs; 2013 Jan; 27(1):67-80. PubMed ID: 23264146
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone: a clinical overview.
Kane JM
J Clin Psychiatry; 2011; 72 Suppl 1():24-8. PubMed ID: 22217440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
